Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aprotinin Clear all
Completed Phase 3 Interventional

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

NCT00668031
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 24, 2026, 11:14 AM EDT
Completed No phase listed Observational

Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.

NCT00405093
View directory record Official record
Conditions
Circulatory Arrest
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Not listed
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 24, 2026, 11:14 AM EDT
Completed No phase listed Observational

Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates

NCT00617955
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Aprotinin, Amicar
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 24, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

FS VH S/D 500 S-apr in Vascular Surgery

NCT00892957
View directory record Official record
Conditions
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Interventions
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Surgical gauze pads
Biological · Other
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Not listed
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 24, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

NCT00306150
View directory record Official record
Conditions
Blood Loss, Surgical, Postoperative Hemorrhage
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 24, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Fibrin Sealant Vascular Surgery Study

NCT00576420
View directory record Official record
Conditions
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Interventions
FS VH S/D 500 s-apr, 60-seconds polymerization time, FS VH S/D 500 s-apr, 120-seconds polymerization time, Manual compression with surgical gauze pads
Biological · Procedure
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Not listed
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 24, 2026, 11:14 AM EDT
No Longer Available No phase listed Expanded access

Aprotinin US Special Access Protocol

NCT00611845
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Aprotinin (Trasylol, BAYA0128)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Decatur, Alabama • Glendale, California • Pismo Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Oct 24, 2026, 11:14 AM EDT
Completed Phase 1 Interventional

Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery

NCT00357851
View directory record Official record
Conditions
Pancreatitis
Interventions
Aprotinin
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Up to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Oct 24, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Fibrin Sealant for the Sealing of Dura Sutures

NCT00681824
View directory record Official record
Conditions
Pathological Processes in the Posterior Fossa, Dura Defects
Interventions
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Standard of care
Biological · Procedure
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
3 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Duarte, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 24, 2026, 11:14 AM EDT
Completed No phase listed Observational

Aprotinin in Neonates Undergoing Cardiopulmonary Bypass

NCT00469742
View directory record Official record
Conditions
Cardiopulmonary Bypass, Congenital Defects, Hemostasis
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 1 Month
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 24, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures

NCT00708071
View directory record Official record
Conditions
Facial Rhytidectomy (Face-lift)
Interventions
Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)
Biological
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
6
States / cities
Beverly Hills, California • Los Angeles, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 24, 2026, 11:14 AM EDT
Terminated Phase 3 Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

NCT00306137
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 24, 2026, 11:14 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Aprotinin in Advanced Breast Cancer

NCT00354900
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Aprotinin
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 24, 2026, 11:14 AM EDT